Ocular Therapeutix INC (OCUL) Stock Price Rose While Opaleye Management INC Has Upped Stake by $4.20 Million

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Logo

Opaleye Management Inc increased its stake in Ocular Therapeutix Inc (OCUL) by 55.26% based on its latest 2019Q2 regulatory filing with the SEC. Opaleye Management Inc bought 1.05M shares as the company’s stock rose 24.66% . The hedge fund held 2.95 million shares of the health care company at the end of 2019Q2, valued at $12.98 million, up from 1.90 million at the end of the previous reported quarter. Opaleye Management Inc who had been investing in Ocular Therapeutix Inc for a number of months, seems to be bullish on the $210.02 million market cap company. The stock increased 0.23% or $0.01 during the last trading session, reaching $4.45. About 289,408 shares traded. Ocular Therapeutix, Inc. (NASDAQ:OCUL) has declined 14.68% since September 13, 2018 and is downtrending. It has underperformed by 14.68% the S&P500.

Opaleye Management Inc, which manages about $151.96M and $328.09 million US Long portfolio, decreased its stake in Axogen Inc (NASDAQ:AXGN) by 200,000 shares to 900,000 shares, valued at $17.82M in 2019Q2, according to the filing.

More notable recent Ocular Therapeutix, Inc. (NASDAQ:OCUL) news were published by: Seekingalpha.com which released: “Ocular up 5% premarket on U.S. reimbursement code for Dextenza – Seeking Alpha” on May 01, 2019, also Seekingalpha.com with their article: “Ocular Therapeutix up 6% premarket on Dextenza reimbursement code – Seeking Alpha” published on July 26, 2019, Businesswire.com published: “Ocular Therapeutixâ„¢ Reports Changes to Board of Directors – Business Wire” on April 23, 2019. More interesting news about Ocular Therapeutix, Inc. (NASDAQ:OCUL) were released by: Finance.Yahoo.com and their article: “Implied Volatility Surging for Ocular (OCUL) Stock Options – Yahoo Finance” published on July 08, 2019 as well as Finance.Yahoo.com‘s news article titled: “Ocular Therapeutixâ„¢ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) – Yahoo Finance” with publication date: July 11, 2019.

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Ratings Coverage

Among 2 analysts covering Ocular Therapeutix (NASDAQ:OCUL), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Ocular Therapeutix has $9 highest and $9 lowest target. $9’s average target is 102.25% above currents $4.45 stock price. Ocular Therapeutix had 6 analyst reports since April 7, 2019 according to SRatingsIntel. The stock of Ocular Therapeutix, Inc. (NASDAQ:OCUL) earned “Buy” rating by JMP Securities on Friday, June 21. The stock of Ocular Therapeutix, Inc. (NASDAQ:OCUL) earned “Buy” rating by H.C. Wainwright on Monday, June 24.

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.